Despite the size of
this patient group, large randomized trials of antithrombotic
therapy in patients with atrial fibrillation
have typically excluded those who also have
moderate-to-severe chronic kidney disease,14-16
and the treatment of these patients has been
based on data obtained from smaller observational
studie